Viking Therapeutics Q3 2026 Earnings Call and Webcast - VIKING THERAPEUTICS INC

Financial Performance:

• Reported a net loss of $183.2 million ($1.55 per share) for the quarter ended September 30, 2026, compared to $90.8 million ($0.81 per share) in the prior year period.
• Research and Development (R&D) expenses increased to $166.8 million for the quarter and $432.7 million for the nine-month period, driven by clinical studies, manufacturing, and personnel costs.
• General and Administrative (G&A) expenses rose to $20.3 million for the quarter and $51.1 million for nine months, fueled by legal, patent services, and consultant fees.
• Cash, cash equivalents, and short-term investments totaled $960 million at quarter-end, a significant increase from $706 million in December 2025.
• The company raised approximately $575 million in gross proceeds from concurrent stock and convertible note offerings, providing substantial runway for development and commercial preparation.
• Management projects average quarterly cash usage of approximately $100 million moving forward, with G&A expected to remain flat until commercialization ramp-up.

Guidance and Future Outlook:

• The Vanquish Phase III subcutaneous studies (Vanquish I and II) are fully enrolled and on track, with plans to initiate patient extension periods in early 2027.
• The Sunrise Phase III oral program has officially commenced, with top-line data expected following 68 weeks of treatment.
• Results from the second part of the maintenance dosing study (evaluating oral and additional subcutaneous regimens) are anticipated in 2027.
• The Phase I single ascending dose (SAD) study for VK3019 is expected to conclude by year-end, leading to a multiple ascending dose (MAD) study in Q1 2027.
• Commercial readiness is progressing with the recruitment of key leadership, including an SVP of Commercial, VP of Market Access, and VP of Medical Affairs, alongside expansion in tech ops, supply chain, and quality compliance.

Business Segments and Product Lines:

• VK2735 (Dual GLP-1/GIP Agonist): The lead program featuring both subcutaneous (injectable) and oral formulations. Phase III Vanquish program targets obesity and type 2 diabetes; Sunrise program targets the same indications for the oral tablet.
• Maintenance Dosing: Phase 1 maintenance study demonstrated that patients could maintain 82–97% of weight loss with every-other-week or monthly subcutaneous dosing, showing tolerability comparable to placebo. Part 2 of this study will evaluate daily oral maintenance doses.
• VK3019 (Amylin/Calcitonin Receptor Agonist): A novel dual agonist currently in Phase I; preclinical data in obese primates showed superior potency compared to VK2735.
• Commercial Strategy: Focus on building a differentiated portfolio offering formulation flexibility (oral vs. injectable) and dosing flexibility (weekly, bi-weekly, monthly) to address long-term weight management needs.

Market and Competitive Landscape:

• Management views VK2735 as potentially the first approved dual GLP-1/GIP agonist with an oral formulation, offering unique switching capabilities between injectable and oral routes.
• Less frequent dosing regimens are positioned as a key differentiator against current weekly-only competitors, aiming to improve patient adherence and quality of life.
• The market is seen as expanding, with initial oral users potentially transitioning to higher-efficacy subcutaneous formulations as the landscape matures.
• Management acknowledges strong competitive efficacy data from competitors (e.g., Zepbound-amylin combinations) but highlights VK3019 as a potential complementary mechanism for non-responders or those intolerant to GLP-1 agonists.

Risks and Challenges:

• Development Risk: Clinical trial outcomes (Vanquish, Sunrise, and VK3019) are unproven and subject to standard regulatory and efficacy uncertainties.
• Tolerability: While current data suggests low GI risks with less frequent dosing, long-term tolerability profiles for oral maintenance and combination therapies remain to be fully established.
• Commercial Execution: Successfully building and scaling the commercial organization, supply chain, and manufacturing capabilities required for a potential launch in ~2.5 years.
• Regulatory Strategy: Uncertainty remains regarding whether maintenance data will be included in the initial NDA filing or submitted later as a supplement.

Management Commentary and Tone:

• Management displayed high confidence in the pipeline's progress, emphasizing that the Vanquish and Sunrise programs are advancing according to plan with strong enrollment.
• Tone was optimistic regarding the "maintenance" concept, positioning the company as a leader in sustainable weight management solutions.
• The tone regarding financials was pragmatic, acknowledging higher R&D/G&A costs as necessary investments for future commercialization.
• Management emphasized the strategic value of having two formulations of the same molecule to reduce adverse event risks through switching.

Analyst Questions and Answers:

• Cross-Trial Comparisons: Management cautioned against direct cross-trial comparisons with competitors, urging investors to evaluate data on a study-by-study basis.
• Dose Selection: The narrowed dose range in the Sunrise study (27.5mg–55mg) was selected to balance potency, patient pill burden, and economic gross margin potential.
• Maintenance Labeling: There is a preference to secure a maintenance indication on the initial label, leveraging extension data from Vanquish and Part 2 maintenance results, though a supplement remains a possibility.
• Pipeline Strategy: The company prefers to focus on internal assets but remains open to in-licensing opportunities that broaden the portfolio, particularly in combination therapy contexts.
• Titration Schedules: Oral titration in Sunrise occurs in 4-week blocks; maintenance studies will explore daily oral doses alongside every-other-week and monthly subcutaneous options.
• Cash Usage: Expected cash burn is approximately $100 million per quarter, with G&A expected to remain flat in the near term before increasing closer to launch.

Other Key Points:

• In the Phase II maintenance study extension, subjects maintained on 17.5mg weekly for 33 weeks achieved a mean weight loss of approximately 22% with no plateau observed.
• VK3019 is being evaluated for potential monotherapy use in GLP-1 intolerant patients or as a combination therapy with VK2735 to leverage non-overlapping mechanisms.
• Overlap between Vanquish and Sunrise clinical trial sites is expected to be significant, leveraging high-performing centers without major enrollment concerns.
• The company highlighted the potential for a "personalized, convenient, and sustainable" weight loss program as a core value proposition.